These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30089306)

  • 1. Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.
    Iddi S; Li D; Aisen PS; Rafii MS; Litvan I; Thompson WK; Donohue MC
    Neurodegener Dis; 2018; 18(4):173-190. PubMed ID: 30089306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations.
    Dinov ID; Heavner B; Tang M; Glusman G; Chard K; Darcy M; Madduri R; Pa J; Spino C; Kesselman C; Foster I; Deutsch EW; Price ND; Van Horn JD; Ames J; Clark K; Hood L; Hampstead BM; Dauer W; Toga AW
    PLoS One; 2016; 11(8):e0157077. PubMed ID: 27494614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.
    Chahine LM; Siderowf A; Barnes J; Seedorff N; Caspell-Garcia C; Simuni T; Coffey CS; Galasko D; Mollenhauer B; Arnedo V; Daegele N; Frasier M; Tanner C; Kieburtz K; Marek K;
    J Parkinsons Dis; 2019; 9(4):665-679. PubMed ID: 31450510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
    Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression marker of Parkinson's disease: a 4-year multi-site imaging study.
    Burciu RG; Ofori E; Archer DB; Wu SS; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
    Brain; 2017 Aug; 140(8):2183-2192. PubMed ID: 28899020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Japan Parkinson's Progression Markers Initiative (J-PPMI).
    Mukai Y; Murata M
    Nihon Rinsho; 2017 Jan; 75(1):151-155. PubMed ID: 30566310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learning.
    Severson KA; Chahine LM; Smolensky LA; Dhuliawala M; Frasier M; Ng K; Ghosh S; Hu J
    Lancet Digit Health; 2021 Sep; 3(9):e555-e564. PubMed ID: 34334334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling a Composite Score in Parkinson's Disease Using Item Response Theory.
    Gottipati G; Karlsson MO; Plan EL
    AAPS J; 2017 May; 19(3):837-845. PubMed ID: 28247193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free-water imaging in Parkinson's disease and atypical parkinsonism.
    Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
    Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of 30 marker candidates in early Parkinson disease as progression markers.
    Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Trautmann E; Zetterberg H; Taylor P; Friede T; Trenkwalder C;
    Neurology; 2016 Jul; 87(2):168-77. PubMed ID: 27164658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study.
    Reinoso G; Allen JC; Au WL; Seah SH; Tay KY; Tan LC
    Eur J Neurol; 2015 Mar; 22(3):457-63. PubMed ID: 24888502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism.
    van Rumund A; Aerts MB; Esselink RAJ; Meijer FJA; Verbeek MM; Bloem BR
    BMC Neurol; 2018 May; 18(1):69. PubMed ID: 29764386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationships between the unified Parkinson's disease rating scale and lower extremity functional performance in persons with early-stage Parkinson's disease.
    Song J; Fisher BE; Petzinger G; Wu A; Gordon J; Salem GJ
    Neurorehabil Neural Repair; 2009 Sep; 23(7):657-61. PubMed ID: 19336530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian latent time joint mixed effect models for multicohort longitudinal data.
    Li D; Iddi S; Thompson WK; Donohue MC;
    Stat Methods Med Res; 2019 Mar; 28(3):835-845. PubMed ID: 29168432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
    Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ
    Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand.
    Løkkegaard A; Werdelin LM; Friberg L
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1623-9. PubMed ID: 12458397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide variant by serum urate interaction in Parkinson's disease.
    Nazeri A; Roostaei T; Sadaghiani S; Chakravarty MM; Eberly S; Lang AE; Voineskos AN
    Ann Neurol; 2015 Nov; 78(5):731-41. PubMed ID: 26284320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.